Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.

Hematology. American Society of Hematology. Education Program - 1 Jan 2015

Abla Oussama, Weitzman Sheila

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a clonally derived neoplasm with a highly variable clinical course. Although LCH was once considered a disorder of immune regulation, the identification of activating mutations in the proto-oncogene BRAF-V600E in ~50%-60% of cases and MEK and ERK phosphorylation in 100% of examined cases, has changed the definition of LCH to a dendritic cell neoplasm with a strong...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Erdheim-Chester Disease
Share to Histiocytosis, Langerhans-Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to MAP Kinase Kinase 1

Share to Proto-Oncogene Mas

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 26637773
DOI: 10.1182/asheducation-2015.1.565

Genes

BRAF
ARAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.PMID 26637773Read ↗

Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics.Semantic proximity Read ↗

Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.Semantic proximity Read ↗

Clinical features and treatment of Langerhans cell histiocytosis.Semantic proximity Read ↗

Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.Semantic proximity Read ↗

[Pathophysiology and treatment of adult Langerhans cell histiocytosis].Semantic proximity Read ↗

Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.Semantic proximity Read ↗

Langerhans cell histiocytosis: current advances in molecular pathogenesis.Semantic proximity Read ↗

BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell HistiocytosisSemantic proximity Read ↗

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesisSemantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.Semantic proximity Read ↗

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.